Profile data is unavailable for this security.
About the company
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
- Revenue in USD (TTM)513.93m
- Net income in USD-110.87m
- Incorporated2012
- Employees610.00
- LocationIntra-Cellular Therapies Inc430 East 29th Street, Suite 900NEW YORK 10016United StatesUSA
- Phone+1 (646) 440-9333
- Fax+1 (302) 655-5049
- Websitehttps://www.intracellulartherapies.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon & Co | 6.35bn | 1.05bn | 5.49bn | 10.00k | 5.24 | 113.80 | 4.25 | 0.8651 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.55bn | 927.00 | -- | 18.69 | -- | 7.14 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.59bn | 373.00 | 18.17 | 31.42 | 13.94 | 6.48 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 5.95bn | 1.31k | 31.56 | 2.83 | 25.82 | 3.22 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.29bn | 411.00 | -- | 3.64 | -- | 1,377.78 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.41bn | 645.00 | -- | 20.63 | -- | 22.72 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.55bn | 2.80k | 21.44 | 1.77 | 6.69 | 1.70 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 6.79bn | 28.00 | -- | 7.27 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.01bn | 610.00 | -- | 10.79 | -- | 13.63 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 7.20bn | 1.80k | -- | 6.19 | -- | 21.00 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 7.54bn | 254.00 | -- | 3.80 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.58bn | 355.00 | -- | 13.41 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.71bn | 420.00 | 41.09 | -- | 32.59 | 4.18 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Elanco Animal Health Inc | 4.37bn | -1.30bn | 8.15bn | 9.30k | -- | 1.35 | -- | 1.87 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Data as of May 23 2024. Currency figures normalised to Intra-Cellular Therapies Inc's reporting currency: US Dollar USD
42.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 11.18m | 10.71% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.97m | 8.59% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.99m | 6.70% |
| Wasatch Advisors, Inc.as of 31 Mar 2024 | 3.85m | 3.70% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 2.82m | 2.70% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 2.48m | 2.37% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.24m | 2.15% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.07m | 1.98% |
| Invesco Advisers, Inc.as of 31 Mar 2024 | 1.83m | 1.76% |
| ClearBridge Investments LLCas of 31 Mar 2024 | 1.74m | 1.67% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
